Recombinant NXPH1 decreases absolute numbers and cycling status of HPCs and mature blood cells in vivo. (A) Change in peripheral blood populations after intravenous injection of recombinant NXPH1 expressed as a percentage of control (at least 3 independent experiments performed in triplicate; percent control is calculated from the control defined as 100%; mean ± SD). (B) Absolute colony number of muBM-derived HPCs 24 hours after exposure to varying doses of recombinant NXPH1 (combined data of 3 independent experiments each performed in triplicate; mean ± SD). (C) Cycling status of muBM-derived HPCs 24 hours after exposure to varying doses of recombinant NXPH1 (combined data of 3 independent experiments each performed in triplicate; mean ± SD). (D) Absolute colony number of muBM-derived HPCs 24, 48, and 72 hours after exposure to DPBS carrier or 5 μg/mouse NXPH1 (combined data of 3 independent experiments each performed in triplicate; mean ± SD). (E) Cycling status of muBM-derived HPCs 24, 48, and 72 hours after exposure to DPBS carrier or 5 μg/mouse NXPH1 (combined data of 3 independent experiments each performed in triplicate; mean ± SD). (F) Change in phenotypically defined muBM progenitor populations 24 hours after intravenous exposure to DPBS carrier or 5 μg/mouse NXPH1 expressed as a percent control (combined data of 3 independent experiments each performed in triplicate; mean ± SD). (G) Absolute colony number of spleen-derived HPCs 24, 48, and 72 hours after exposure to DPBS carrier or 5 μg/mouse NXPH1 (combined data of 3 independent experiments each performed in triplicate; mean ± SD). (H) Cycling status of spleen-derived HPCs 24, 48, and 72 hours after exposure to DPBS carrier or 5 μg/mouse NXPH1 (combined data of 3 independent experiments each performed in triplicate; mean ± SD). *P < .05, **P < .005, ***P < .0005.